Travere Therapeutics Q3 Swings to Loss, Revenue Rises

05:27 PM EST, 11/02/2026 (MT Newswires) -- Travere Therapeutics (TVTX) reported a Q3 adjusted loss late Monday of $0.31 per diluted share, swinging from a profit of $0.59 a year earlier. Analysts polled by FactSet expected an income of $0.56 per share. Revenue for the three months ended Sept. 30 was $224.6 million, compared with $164.9 million a year earlier. Analysts expected $195.3 million.